BACKGROUND: Activated leucocyte cell adhesion molecule (ALCAM) has been implicated in tumorigenesis and tumour progression of malignant melanoma and prostate cancer. AIMS: To clarify the expression patterns of ALCAM in colon cancer and to correlate these with clinicopathological parameters, including patient survival. METHODS: One hundred and eleven colorectal carcinomas were immunostained for ALCAM (clone MOG/07) using a standard detection system. Cytoplasmic and membranous immunoreactivity were scored semiquantitatively. Fisher's exact test, chi2 test for trends, Kaplan-Meier analysis, and Cox's regression were applied. RESULTS: In colorectal cancer, 58.6% and 30.6% of cases showed strong cytoplasmic and membranous expression of ALCAM, respectively. No significant correlation with patient age, tumour grade, stage, or nodal status was apparent. In survival analyses, membranous ALCAM expression correlated significantly (Cox's regression, p=0.028; relative risk, 2.3) with shortened patient survival. CONCLUSIONS: ALCAM is frequently upregulated in colorectal cancer and is a new independent prognostic marker, underscoring the importance of ALCAM in tumour progression in this disease.
BACKGROUND:Activated leucocyte cell adhesion molecule (ALCAM) has been implicated in tumorigenesis and tumour progression of malignant melanoma and prostate cancer. AIMS: To clarify the expression patterns of ALCAM in colon cancer and to correlate these with clinicopathological parameters, including patient survival. METHODS: One hundred and eleven colorectal carcinomas were immunostained for ALCAM (clone MOG/07) using a standard detection system. Cytoplasmic and membranous immunoreactivity were scored semiquantitatively. Fisher's exact test, chi2 test for trends, Kaplan-Meier analysis, and Cox's regression were applied. RESULTS: In colorectal cancer, 58.6% and 30.6% of cases showed strong cytoplasmic and membranous expression of ALCAM, respectively. No significant correlation with patient age, tumour grade, stage, or nodal status was apparent. In survival analyses, membranous ALCAM expression correlated significantly (Cox's regression, p=0.028; relative risk, 2.3) with shortened patient survival. CONCLUSIONS:ALCAM is frequently upregulated in colorectal cancer and is a new independent prognostic marker, underscoring the importance of ALCAM in tumour progression in this disease.
Authors: W G Degen; L C van Kempen; E G Gijzen; J J van Groningen; Y van Kooyk; H P Bloemers; G W Swart Journal: Am J Pathol Date: 1998-03 Impact factor: 4.307
Authors: S Choi; M Kobayashi; J Wang; H Habelhah; F Okada; J Hamada; T Moriuchi; Y Totsuka; M Hosokawa Journal: Clin Exp Metastasis Date: 2000 Impact factor: 5.150
Authors: T A Stamey; J A Warrington; M C Caldwell; Z Chen; Z Fan; M Mahadevappa; J E McNeal; R Nolley; Z Zhang Journal: J Urol Date: 2001-12 Impact factor: 7.450
Authors: O Ohneda; K Ohneda; F Arai; J Lee; T Miyamoto; Y Fukushima; D Dowbenko; L A Lasky; T Suda Journal: Blood Date: 2001-10-01 Impact factor: 22.113
Authors: Ahmedin Jemal; Taylor Murray; Alicia Samuels; Asma Ghafoor; Elizabeth Ward; Michael J Thun Journal: CA Cancer J Clin Date: 2003 Jan-Feb Impact factor: 508.702
Authors: M A Bowen; D D Patel; X Li; B Modrell; A R Malacko; W C Wang; H Marquardt; M Neubauer; J M Pesando; U Francke Journal: J Exp Med Date: 1995-06-01 Impact factor: 14.307
Authors: Jonas Vikesaa; Thomas V O Hansen; Lars Jønson; Rehannah Borup; Ulla M Wewer; Jan Christiansen; Finn C Nielsen Journal: EMBO J Date: 2006-03-16 Impact factor: 11.598
Authors: Richard Tavaré; Wei H Wu; Kirstin A Zettlitz; Felix B Salazar; Katelyn E McCabe; James D Marks; Anna M Wu Journal: Protein Eng Des Sel Date: 2014-08-04 Impact factor: 1.650
Authors: C Kahlert; H Weber; C Mogler; F Bergmann; P Schirmacher; H G Kenngott; U Matterne; N Mollberg; N N Rahbari; U Hinz; M Koch; M Aigner; J Weitz Journal: Br J Cancer Date: 2009-07-14 Impact factor: 7.640